Supplementary details reveal how UBE2T enhances nucleolar function, promoting cancer progression through IDH1 and TP53 mutations.
Supplementary Figure S7: Supplementary materials for in vivo and in vitro experiments of Figure 6 in main text.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: